Esbriet, Ofev Reviews Convinced FDA Of Acceptable IPF Endpoint
Executive Summary
FDA leaders explain in NEJM how they came to accept a measure of lung function as a surrogate for mortality in trials of idiopathic pulmonary fibrosis therapies. See how agency reviewers handled this in a preview of our upcoming Drug Review Profile series.
You may also be interested in...
Pliant Sees Treating Fibrosis As Primary Goal, Not Add-On
The start-up will advance UCSF research on fibrosis to improve upon current treatments for idiopathic pulmonary fibrosis, and possibly create therapeutics for fibrosis of the liver, kidneys and GI tract as well.
Pliant Sees Treating Fibrosis As Primary Goal, Not Add-On
Start-up will advance UCSF research on fibrosis to improve upon current treatments for idiopathic pulmonary fibrosis, and possibly create therapeutics for fibrosis of the liver, kidneys and GI tract as well.
When Should Unmet Need Trump Inadequate Data?
The Esbriet review exemplifies FDA’s eternal struggle between requiring adequate evidence of efficacy and giving patients with deadly diseases a chance at treatment.